Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Read more about Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Read more about A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Read more about A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Read more about Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
Cyclooxygenase-2: a therapeutic target for prostate cancer. Read more about Cyclooxygenase-2: a therapeutic target for prostate cancer.
